Aldosteronomas-State of the Art

Surgical Clinics of North America

Volumn 89, Issue 5, 2009, Pages 1241-1253

  McKenzie, Travis J ^a   Lillegard, Joseph B ^a   Young Jr , William F ^a   Thompson, Geoffrey B ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adrenal vein sampling; Aldosterone producing adenoma; Aldosteronoma; Idiopathic hyperplasia; Primary aldosteronism

Indexed keywords

EPLERENONE; SPIRONOLACTONE;

ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; GYNECOMASTIA; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOKALEMIA; IMPOTENCE; LAPAROSCOPIC SURGERY; MENSTRUAL IRREGULARITY; OUTCOME ASSESSMENT; PLASMA RENIN ACTIVITY; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; REVIEW;

ADRENAL CORTEX NEOPLASMS; ADRENAL GLANDS; ADRENALECTOMY; ADRENOCORTICAL ADENOMA; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 70349850949     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2009.06.017     Document Type: Review

References (93)

1. Conn J.W. Presidential address. Part I, painting background. Part II, primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45 1 (1955) 3-17
2. AACE Hypertension Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of hypertension. Endocr Pract 12 2 (2006) 193-222
3. Tucker R.M., and Labarth D.R. Frequency of surgical treatment for hypertension in adults at the Mayo clinic from 1973 through 1975. Mayo Clin Proc 52 9 (1977) 549-555
4. Anderson Jr. G.H., Blakeman N., and Streeten D.H. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 12 5 (1994) 609-615
5. Rossi E., Regolisti G., Negro A., et al. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 15 10 Pt 1 (2002) 896-902
6. Gordon R.D., Stowasser M., Tunny T.J., et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 21 14 (1994) 315-318
7. Kumar A., Lall S.B., Ammini A., et al. Screening of a population of young hypertensives for primary hyperaldosteronism. J Hum Hypertens 8 9 (1994) 731-732
8. Kreze Jr. A., Okalova D., Vanuga P., et al. Occurrence of primary aldosteronism in a group of ambulatory hypertensive patients. Vnitr Lek 45 1 (1999) 17-21
9. Lim P.O., Dow E., Brennan G., et al. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 14 5 (2000) 311-315
10. Loh K.C., Koay E.S., Khaw M.C., et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 85 8 (2000) 2854-2859
11. Fardella C.E., Mosso L., Gomez-Sanchez C., et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85 5 (2000) 1863-1867
12. Schwartz G.L., and Turner S.T. Prevalence of unrecognized primary aldosteronism in essential hypertension. [abstract]. Am J Hypertens 15 (2002) 18A
13. Sawka A.M., Young Jr. W.F., Thompson G.B., et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 135 4 (2001) 258-261
14. Young Jr. W.F. Primary aldosteronism: management issues. Ann N Y Acad Sci 970 (2002) 61-76
15. Calhoun D.A., Nishizaka M.K., Zaman M.A., et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40 6 (2002) 892-896
16. Mulatero P., Rabbai F., Milan A., et al. Drug effects on aldosterone/plasma renin activity ration in primary hyperaldosteronism. Hypertension 40 6 (2002) 897-902
17. Young Jr. W.F. Minireview: primary aldosteronism-changing concepts in diagnosis and treatment. Endocrinology 144 6 (2003) 2208-2213
18. Ganguly A., Zager P., and Luetscher J. Primary aldosteronism due to unilateral adrenal hyperplasia. J Clin Endocrinol Metab 51 5 (1980) 1190-1194
19. Irony I., Kater C., Biglieri E., et al. Correctable subsets of primary aldosteronism. Am J Hypertens 3 7 (1990) 576-582
20. Doppman J.L., and Gill Jr. J.R. Hyperaldosteronism: sampling the adrenal veins. Radiology 198 2 (1996) 309-312
21. Young Jr. W.F., Stanson A.W., Grant C.S., et al. Primary aldosteronism: adrenal venous sampling. Surgery 120 6 (1996) 913-920
22. Rossi G.P., Sacchetto A., Chiesura-Corona M., et al. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 86 3 (2001) 1083-1090
23. McMahon G.T., and Dluhy R.G. Glucocorticoid-remediable aldosteronism. Cardiol Rev 12 1 (2004) 44-48
24. Lifton R.P., Dluhy R.G., Powers M., et al. A chimeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remedial aldosteronism and human hypertension. Nature 355 6357 (1992) 262-265
25. Jackson R.V., Lafferty A., Torpy D.J., et al. New genetic insights in familial hyperaldosteronism. Ann N Y Acad Sci 970 (2002) 77-88
26. Lifton R.P., Dluhy R.G., Powers M., et al. Hereditary hypertension caused by chimaeric gene duplication and ectopic expression of aldosterone synthase. Nat Genet 2 1 (1992) 66-74
27. Lins P., and Adamson U. Primary aldosteronism: a follow-up study of 28 cases of surgically treated aldosterone-producing adenomas. Acta Med Scand 221 3 (1987) 275-282
28. Vetter H., Fischer M., Galanski M., et al. Primary aldosteronism: diagnosis and noninvasive lateralization procedures. Cardiology 72 Suppl 1 (1985) 57-63
29. Celen O., O'Brien M.J., Melby J.C., et al. Factors influencing outcome of surgery for primary aldosteronism. Arch Surg 131 6 (1996) 646-650
30. Favia G., Lumachi F., Scarpa V., et al. Adrenalectomy in primary aldosteronism: a long-term follow-up study in 52 patients. World J Surg 16 4 (1992) 680-683
31. Lo C.Y., Tam P.C., Kung A.W., et al. Primary aldosteronism. Results of surgical treatment. Ann Surg 224 2 (1996) 125-130
32. Milsom S.R., Espiner E.A., Nicholls M.O., et al. The blood pressure response to unilateral adrenalectomy in primary aldosteronism. Q J Med 61 236 (1986) 1141-1151
33. Proye C.A., Mulliez E.A., Carnaille B.M., et al. Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism?. Surgery 124 6 (1998) 1128-1133
34. Huang Y.Y., Hsu B.R., and Tsai J.S. Paralytic myopathy-a leading clinical presentation for primary aldosteronism in Taiwan. J Clin Endocrinol Metab 81 11 (1996) 4038-4041
35. Obara T., Ito Y., and Iihara M. Hyperaldosteronism. In: Clark O.H., Duh Q.-Y., and Kebebew E. (Eds). Textbook of endocrine surgery. 2nd edition (2005), Elsevier Saunders, Philadelphia 595-603
36. Young Jr. W.F., and Klee G. Primary aldosteronism. Diagnostic evaluation. Endocrinol Metab Clin North Am 17 2 (1988) 367-395
37. Streeten D.H., Tomycz N., and Anderson G.H. Reliability of screening methods for the diagnosis of primary aldosteronism. Am J Med 67 3 (1979) 403-413
38. Bravo E.L. Primary aldosteronism. Issues in diagnosis and management. Endocrinol Metab Clin North Am 23 2 (1994) 271-283
39. Melby J.C. Clinical review 1: endocrine hypertension. J Clin Endocrinol Metab 69 4 (1989) 697-703
40. Hiramatsu K., Yamada T., Yukimura Y., et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Arch Intern Med 141 12 (1981) 1589-1593
41. Hamlet S.M., Tunny T.J., Woodland E., et al. Is aldosterone/renin ratio useful to screen a hypertensive population for primary aldosteronism?. Clin Exp Pharmacol Physiol 12 3 (1985) 249-252
42. Weinberger M.H., and Fineberg N.S. The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med 153 18 (1993) 2125-2129
43. Young Jr. W.F. Primary aldosteronism: a common and curable form of hypertension. Cardiol Rev 7 4 (1999) 207-214
44. Young Jr. W.F. Primary aldosteronism: update on diagnosis and treatment. Endocrinologist 7 4 (1997) 213-221
45. Young Jr. W.F. Management approaches to adrenal incidentaloma. A view from Rochester, Minnesota. Endocrinol Metab Clin North Am 29 1 (2000) 159-185
46. Lim P.O., Young W.F., and MacDonald T.M. A review of the medical treatment of primary aldosteronism. J Hypertens 19 3 (2001) 353-361
47. Montori V.M., and Young Jr. W.F. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism: a systematic review of the literature. Endocrinol Metab Clin North Am 31 3 (2002) 619-632
48. Young Jr. W.F. Primary aldosteronism - treatment options. Growth Horm IGF Res 13 Suppl A (2003) S102-S108
49. Gordon R.D., Ziesak M.D., Tunny T.J., et al. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 20 5 (1993) 296-298
50. Lyons D.F., Kemn D.C., Brown R.D., et al. Single dose captopril as a diagnostic test for primary aldosteronism. J Clin Endocrinol Metab 57 5 (1983) 892-896
51. Ganguly A., Melada G.A., Luetscher J.A., et al. Control of plasma aldosterone in primary aldosteronism: distinction between adenoma and hyperplasia. J Clin Endocrinol Metab 37 5 (1973) 765-775
52. Obara T., Ito Y., Okamoto T., et al. Risk factors associated with postoperative persistent hypertension in patients with primary aldosteronism. Surgery 112 6 (1992) 987-993
53. McLeod M., Thompson N., Gross M., et al. Idiopathic aldosteronism masquerading as discrete aldosterone-secreting adrenal cortical neoplasms among patients with primary aldosteronism. Surgery 106 6 (1989) 1161-1167
54. Nomura K., Toraya S., Horiba N., et al. Plasma aldosterone response to upright posture and angiotensin II infusion in aldosterone-producing adenoma. J Clin Endocrinol Metab 75 1 (1992) 323-326
55. Kem D.C., Tang K., Hanson C.S., et al. The prediction of anatomical morphology of primary aldosteronism using serum 18-hydroxycorticosterone. J Clin Endocrinol Metab 60 1 (1985) 67-73
56. Gross M., and Shapiro B. Scintigraphic studies in adrenal hypertension. Semin Nucl Med 19 2 (1989) 122-143
57. Hollak C.E., Prummel M.F., and Tiel-van Buul M.M. Bilateral adrenal tumours in primary aldosteronism: localization of a unilateral aldosteronoma by dexamethasone suppression scan. J Intern Med 229 6 (1991) 545-548
58. Nomura K., Kusakabe K., Maki M., et al. Iodomethylnorcholesterol uptake in an aldosteronoma shown by dexamethasone-suppression scintigraphy: relationship to adenoma size and functional activity. J Clin Endocrinol Metab 71 4 (1990) 825-830
59. Gleason P.E., Weinberger M.H., Pratt J.H., et al. Evaluation of diagnostic tests in the differential diagnosis of primary aldosteronism: unilateral adenoma versus bilateral micronodular hyperplasia. J Urol 150 5 Pt 1 (1993) 1365-1368
60. Weigel R.J., Wells S.A., Gunnells J.C., et al. Surgical treatment of primary hyperaldosteronism. Ann Surg 219 4 (1994) 347-352
61. Young Jr. W.F., Stanson A.W., Thompson G.B., et al. Role for adrenal venous sampling in primary aldosteronism. Surgery 136 12 (2004) 1227-1235
62. Rocha R., Rudolph A.E., Frierdich G.E., et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283 5 (2002) H1802-H1810
63. Rocha R., and Funder J.W. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 970 (2002) 89-100
64. Stier Jr. C.T., Chander P.N., and Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 10 2 (2002) 97-107
65. Martinez D.V., Rocha R., Mastumura M., et al. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension 39 2 Pt 2 (2002) 614-618
66. Brilla C.G., Pick R., Tan L.B., et al. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67 6 (1990) 1355-1364
67. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 10 (1999) 709-717
68. Rocha R., and Williams G.H. Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs 62 5 (2002) 723-731
69. Alderman M.H., Madhavan S., Ooi W.L., et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 324 16 (1991) 1098-1104
70. Vaughan D.E., Lazos S.A., and Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 95 3 (1995) 995-1001
71. Kerins D.M., Hao Q., and Vaughan D.E. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 96 5 (1995) 2515-2520
72. Brown N.J., Kim K.S., Chen Y.Q., et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 85 1 (2000) 336-344
73. Brown N.J., Agirbasli M.A., Williams G.H., et al. Effect of activation and inhibition of renin angiotensin system on plasma PAI-1. Hypertension 32 6 (1998) 965-971
74. Sawathiparnich P., Kumar S., Vaughan D.E., et al. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-a in humans. J Clin Endocrinol Metab 87 2 (2002) 448-452
75. Jeunemaitre X., Chatellier G., Kreft-Jais C., et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 60 10 (1987) 820-825
76. Zillich A.J., and Carter B.L. Eplerenone: a novel selective aldosterone blocker. Ann Pharmacother 36 10 (2002) 1567-1576
77. de Gasparo M., Joss U., Ramjoue H.P., et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 240 2 (1987) 650-656
78. Weinberger M.H., Roniker B., Krause S.L., et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 15 8 (2002) 709-716
79. Krum H., Nolly H., Workman D., et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 40 2 (2002) 117-123
80. Gagner M. Laparoscopic adrenalectomy. Surg Clin North Am 76 3 (1996) 523-537
81. Kebebew E., Siperstein A.E., and Duh Q.Y. Laparoscopic adrenalectomy: the optimal surgical approach. J Laparoendosc Adv Surg Tech A 11 6 (2001) 409-413
82. Marescaux J., Mutter D., and Wheeler M.H. Laparoscopic right and left adrenalectomies. Surgical procedures. Surg Endosc 10 9 (1996) 912-915
83. Gagner M., Lacroix A., Prinz R.A., et al. Early experience with laparoscopic approach for adrenalectomy. Surgery 114 6 (1993) 1120-1124
84. Higashihara E., Tanaka Y., Hori S., et al. Laparoscopic adrenalectomy: the initial three cases. J Urol 149 5 (1993) 973-976
85. Suzuki K., Kageyama S., Ueda D., et al. Laparoscopic adrenalectomy: clinical, experience with 12 cases. J Urol 150 4 (1993) 1099-1102
86. Linos D.A., Stylopoulos N., Boukis M., et al. Anterior, posterior, or laparoscopic approach for the management of adrenal diseases?. Am J Surg 173 2 (1997) 120-125
87. Prinz R.A. A comparison of laparoscopic and open adrenalectomies. Arch Surg 130 5 (1995) 489-492
88. Thompson G.B., Grant C.S., van Heerden J.A., et al. Laparoscopic versus open posterior adrenalectomy: a case-control study of 100 patients. Surgery 122 6 (1997) 1132-1136
89. Walz M.K., Alesina R.F., Wenger A., et al. Posterior retroperitoneoscopic adrenalectomy-results of more than 500 procedures. Surgery 140 6 (2006) 943-948
90. Gagner M., Lacroix A., and Bolte E. Laparoscopic adrenalectomy in Cushing's syndrome and pheochromocytoma. N Engl J Med 327 14 (1992) 1033
91. Mercan S., Seven R., Ozarmagan S., et al. Endoscopic retroperitoneal adrenalectomy. Surgery 118 6 (1995) 1071-1075
92. Ferriss J.B., Brown J.J., Fraser R., et al. Results of adrenal surgery in patients with hypertension, aldosterone excess, and low plasma renin concentration. Br Med J 1 5950 (1975) 135-138
93. Hunt T., Schambelan M., and Biglieri E. Selection of patients and operative approach in aldosteronism. Ann Surg 182 4 (1975) 353-361